Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
Irinotecan liposome injection (Onivyde), in combination with leucovorin and 5-FU, was approved by the FDA in October 2015 as the only treatment option for patients with advanced or metastatic pancreatic cancer that progressed after gemcitabine-based chemotherapy.
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Results 1 - 5 of 5